MULTIPLE SCLEROSIS JOURNAL, cilt.22, sa.4, ss.520-532, 2016 (SCI-Expanded)
Objective: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatment utilisation and persistence in an international cohort of patients with multiple sclerosis (MS).